The article says Vivos shares rose 18% after hours, but gives no company news explaining the move. The share-price change alone does not change Vivos's business outlook.
A share-price move shows how traders reacted, not whether Vivos can sell more products, earn more, or face new costs. The article gives no business reason for the move, so it does not change the view of Vivos's outlook.
The article says SCWorx shares rose about 11% after hours, but gives no company news explaining the move. The share-price change alone does not change SCWorx's business outlook.
The article says Metagenomi Therapeutics shares rose about 10% after hours, but gives no company news explaining the move. The share-price change alone does not change its business outlook.
The article says TScan Therapeutics shares rose about 9% after hours, but gives no company news explaining the move. The share-price change alone does not change its business outlook.
The article says Karyopharm Therapeutics shares rose about 8% after hours, but gives no company news explaining the move. The share-price change alone does not change its business outlook.
The article says Neumora Therapeutics shares rose about 7% after hours, but gives no company news explaining the move. The share-price change alone does not change its business outlook.
Follow Vivos Therapeutics (VVOS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VVOS